Advanced Search

Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2013 February;79(2) > Minerva Anestesiologica 2013 February;79(2):200-8



A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care

Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036

Frequency: Monthly

ISSN 0375-9393

Online ISSN 1827-1596


Minerva Anestesiologica 2013 February;79(2):200-8


Colistin in critically ill patients

Boisson M. 1, 2, Gregoire N. 1, Couet W. 1, 3, Mimoz O. 1, 2

1 Inserm U1070, Faculty of Medicine and Pharmacy, University of Poitiers, Poitiers, France;
2 Department of Anesthesiology and Intensive Care Unit, University Hospital of Poitiers, Poitiers, France;
3 Toxicology and Pharmacokinetic Unit, University Hospital of Poitiers, Poitiers, France

Colistin is a re-emerging old antibiotic that is used as a salvage treatment against multidrug-resistant Gram-negative infections. Because it is administrated as an inactive prodrug, colistin methanesulfonate (CMS) that undergoes rapid hydrolyze to colistin, pharmacokinetic studies using biological assays are unreliable. With the recent development of new assays using high performance liquid chromatography (HPLC) accurate pharmacokinetic of CMS and formed colistin is now available in various populations. This article aims to update previous reports on pharmacodynamics, pharmacokinetics, safety and clinical use of colistin, with a special focus on data useful to treat critically ill patients.

language: English


top of page